Edward Nash
Stock Analyst at Canaccord Genuity
(3.88)
# 515
Out of 4,818 analysts
79
Total ratings
44.93%
Success rate
10.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Edward Nash
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintains: Buy | $45 → $47 | $16.68 | +181.77% | 10 | Apr 10, 2025 | |
| CORT Corcept Therapeutics | Maintains: Buy | $130 → $142 | $69.27 | +104.99% | 7 | Apr 1, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $9 | $1.15 | +682.61% | 2 | Feb 26, 2025 | |
| VRNA Verona Pharma | Maintains: Buy | $44 → $72 | $63.00 | +14.29% | 9 | Feb 12, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Hold | $4 | $1.55 | +158.06% | 2 | Feb 10, 2025 | |
| AKRO Akero Therapeutics | Maintains: Buy | $56 → $73 | $39.65 | +84.11% | 6 | Jan 28, 2025 | |
| APGE Apogee Therapeutics | Initiates: Buy | $89 | $36.59 | +143.24% | 1 | Nov 25, 2024 | |
| VTYX Ventyx Biosciences | Maintains: Buy | $15 → $14 | $1.15 | +1,117.39% | 6 | Aug 12, 2024 | |
| CRDL Cardiol Therapeutics | Maintains: Buy | $6 → $8 | $1.08 | +640.74% | 3 | May 23, 2024 | |
| IVA Inventiva | Maintains: Buy | $12 → $20 | $3.88 | +415.46% | 2 | Apr 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $338 → $377 | $309.32 | +21.88% | 8 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $8 | $2.70 | +196.30% | 4 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $17 | $3.97 | +328.21% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $3 → $2 | $2.30 | -13.04% | 4 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $900 → $180 | $1.61 | +11,080.12% | 2 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $82 | $37.38 | +119.37% | 6 | Jun 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $80 | $2.87 | +2,687.46% | 3 | Sep 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $14.41 | +233.10% | 1 | May 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $650 | $5.22 | +12,352.11% | 1 | Nov 8, 2017 |
Travere Therapeutics
Apr 10, 2025
Maintains: Buy
Price Target: $45 → $47
Current: $16.68
Upside: +181.77%
Corcept Therapeutics
Apr 1, 2025
Maintains: Buy
Price Target: $130 → $142
Current: $69.27
Upside: +104.99%
Rani Therapeutics Holdings
Feb 26, 2025
Maintains: Buy
Price Target: $9
Current: $1.15
Upside: +682.61%
Verona Pharma
Feb 12, 2025
Maintains: Buy
Price Target: $44 → $72
Current: $63.00
Upside: +14.29%
Pliant Therapeutics
Feb 10, 2025
Downgrades: Hold
Price Target: $4
Current: $1.55
Upside: +158.06%
Akero Therapeutics
Jan 28, 2025
Maintains: Buy
Price Target: $56 → $73
Current: $39.65
Upside: +84.11%
Apogee Therapeutics
Nov 25, 2024
Initiates: Buy
Price Target: $89
Current: $36.59
Upside: +143.24%
Ventyx Biosciences
Aug 12, 2024
Maintains: Buy
Price Target: $15 → $14
Current: $1.15
Upside: +1,117.39%
Cardiol Therapeutics
May 23, 2024
Maintains: Buy
Price Target: $6 → $8
Current: $1.08
Upside: +640.74%
Inventiva
Apr 8, 2024
Maintains: Buy
Price Target: $12 → $20
Current: $3.88
Upside: +415.46%
Mar 15, 2024
Maintains: Buy
Price Target: $338 → $377
Current: $309.32
Upside: +21.88%
Jul 3, 2023
Assumes: Hold
Price Target: $8
Current: $2.70
Upside: +196.30%
May 19, 2023
Maintains: Buy
Price Target: $16 → $17
Current: $3.97
Upside: +328.21%
May 17, 2023
Maintains: Hold
Price Target: $3 → $2
Current: $2.30
Upside: -13.04%
Aug 8, 2022
Downgrades: Hold
Price Target: $900 → $180
Current: $1.61
Upside: +11,080.12%
Jun 19, 2020
Maintains: Buy
Price Target: $80 → $82
Current: $37.38
Upside: +119.37%
Sep 13, 2019
Maintains: Hold
Price Target: $120 → $80
Current: $2.87
Upside: +2,687.46%
May 24, 2018
Initiates: Buy
Price Target: $48
Current: $14.41
Upside: +233.10%
Nov 8, 2017
Initiates: Buy
Price Target: $650
Current: $5.22
Upside: +12,352.11%